<DOC>
	<DOCNO>NCT01715519</DOCNO>
	<brief_summary>The purpose study determine whether vilazodone effective treatmen Posttraumatic Stress Disorder ( PTSD ) co-morbid mild depression .</brief_summary>
	<brief_title>Vilazodone Treatment Posttraumatic Stress Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Participants must satisfy DSMIV diagnostic criterion chronic PTSD Evidence PTSD disease base upon one following : Mild great depression Beck Depression Inventory II ( BDIII , score &gt; 12 ) . May symptom comorbid PTSD ( e.g. , anxiety somatic pain ) Ability comprehend satisfactorily comply protocol require sign write informed consent prior enter study procedure May psychotherapy initiate least three month prior screen visit . Subject must discontinue otherwise alter therapy study . Subject may take psychopharmacological medication within 7 day prior Baseline visit . Negative urine pregnancy test screen visit duration study woman childbearing potential . Patients concurrent DSMIV Axis I diagnosis follow category : 1 . Delirium , Dementia , Amnestic Cognitive disorder 2 . Lifetime Schizophrenia Psychotic Disorders 3. lifetime Bipolar I Disorder 4 . BipolarII Disorder episode hypomania within last year 5 . Alcohol Substance Dependence Abuse ( exclude nicotine ) one month prior Screening Visit 6 . Any concurrent Axis I Disorder ( include Major Depressive Disorder ) must secondary primary diagnosis PTSD . Decisional incapacity ( dementia ) Use centrally act medication potentially effect biological expression Chronic pain level require use opiate medication Known exposure chemical physical trauma cause neuropsychiatric sequela Past chronic PTSD History 2 treatment failure SSRIs give primarily treatment PTSD , adequate Investigator 's opinion , least 8 week History intolerance hypersensitivity SSRI 's History seizures Significant risk commit suicide , homicidal violent Investigator 's opinion significant imminent risk hurt others Treated depotneuroleptic within 3 month MAO inhibitor within 30 day prior Baseline visit Received ECT within 3 month prior Screening visit Pregnant nursing , woman childbearing potential sexually active use adequate contraception , judge unreliable use contraception Positive urine drug screen , unless prove prescribed shortterm course treatment . Drug screen must repeat least 7 day last dose prescription medication contain narcotic A medical condition , Investigator 's opinion , would expose increase risk significant adverse event interfere assessment safety efficacy course trial Requiring concomitant treatment psychotropic drug ( except zolpidem sleep ) Plans initiate terminate form psychotherapy behavior therapy study Receiving disability payment ( &gt; 50 % service connection total Social Security ) involve litigation PTSD psychiatric illness . Unable speak , read , understand English judge investigator unable unlikely follow study protocol complete schedule visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Vilazodone</keyword>
	<keyword>PTSD</keyword>
	<keyword>Depression</keyword>
</DOC>